Loading
MT-601 is an experimental autologous multi-antigen recognizing T cell therapy, not genetically modified from Marker Therapeutics, in phase 1 trials for relapsed lymphoma and pancreatic cancer.
MT-601 is an autologous multi-antigen recognizing (MAR) T cell therapy, not genetically modified from Marker Therapeutics. Multi-antigen specific CD4+ and CD8+ T cells that recognise six tumour antigens (Survivin, PRAME, NY-ESO-1, MAGE-A4, SSX2, WT-1), designed to recognise and kill tumours without genetic modification. Its furthest stage is phase 1, for relapsed lymphoma (including after or ineligible for anti-CD19 CAR-T) and pancreatic cancer. ClinicalTrials.gov registers it in 2 studies linked below. Lymphoma study NCT05798897 recruiting (phase 1); pancreatic study NCT06549751 registered, not yet recruiting (phase 1). Whether it works in people has not been established unless a trial below reports it.
1.MT-601 slips into a pocket on BIRC5.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"MT-601" OR ABSTRACT:"MT-601") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MT-601, not a curated reading list.
Shares WT1 and the tag pipeline.
Shares PRAME and the tag pipeline.
Shares PRAME and the tag pipeline.
Shares PRAME and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/